Research programme: TRPV cation channel inhibitors - Purdue Pharma

Drug Profile

Research programme: TRPV cation channel inhibitors - Purdue Pharma

Alternative Names: BCTC; Research programme: vanilloid receptor 1 antagonists - Purdue Pharma

Latest Information Update: 21 Jul 2010

Price : $50

At a glance

  • Originator Purdue Pharma
  • Class Piperazines
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 21 Jul 2010 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 23 Sep 2003 Preclinical trials in Pain in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top